Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 18 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Raises More Than $42 Million, Completes Sarfartoq Field Program
Greenland Mines (NASDAQ: GRML) raised more than $42 million from existing investors through a registered…
-
QualityStocksNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Featured in AINewsWire Editorial on Natural Hydrogen, AI Energy Demand
This article has been disseminated on behalf of MAX Power Mining and may include paid…
-
QualityStocksNewsBreaks – Frontieras North America Selects Kiewit for FEED of Mason County Facility
Frontieras North America announced that it selected Kiewit Engineering Group Inc., a subsidiary of Kiewit…